In a phase I trial of Venetoclax (a BCL2 inhibitor), most patients with refractory chronic lymphocytic leukemia (CLL) had a partial response, while patients with chromosome 17p deletion achieved a complete response. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.